Treatment(s) now being considered-Lumpectomy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Lumpectomy Posts on Medivizor

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Posted by on May 28, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to...

Read More

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Posted by on Jan 15, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the frequency and severity of neuropathy (nerve damage) eribulin (Halaven) with paclitaxel (Taxol) given before surgery in women with operable breast cancer (BC). The study found that the frequency and severity of neuropathy were reduced in patients who received eribulin than in patients who received...

Read More

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Posted by on May 8, 2022 in Breast cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...

Read More

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Posted by on Apr 26, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the oncological effectiveness of intraoperative radiotherapy (IORT) and whole breast irradiation (WBI) for patients with early breast cancer (BC).  This study concluded that there was a high oncological effectiveness for both groups of patients.  Some background Intraoperative...

Read More

Does lumpectomy followed by radiation improve survival outcomes in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes?

Does lumpectomy followed by radiation improve survival outcomes in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes?

Posted by on Aug 22, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the survival outcomes after lumpectomy followed by radiation versus mastectomy alone in patients with early-stage HER2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC) with low or high tumor-infiltrating lymphocytes (TILs). The data showed that lumpectomy followed by radiation improves...

Read More

Is a regimen of weekly chemotherapy with trastuzumab and pertuzumab as effective as standard treatment options for HER2-positive breast cancer

Is a regimen of weekly chemotherapy with trastuzumab and pertuzumab as effective as standard treatment options for HER2-positive breast cancer

Posted by on Aug 8, 2021 in Breast cancer | 0 comments

In a nutshell This study examined the use of paclitaxel (Taxol) and carboplatin (Paraplatin) as weekly chemotherapy (CT) with trastuzumab (Herceptin) and pertuzumab (Perjeta) in HER2+ breast cancer (BC) in order to reduce toxicity rates. The authors found that the weekly regimen of chemotherapy can be considered an alternative to standard chemotherapy...

Read More

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study looked at the timing of chemotherapy (CT) after surgery in the treatment of early breast cancer (BC). The authors found that CT given within 31 days after surgery may improve survival in patients with triple-negative (TN) BC.  Some background BC is one of the most common types of cancer found in women. There are...

Read More

Comparing 2 radiation treatments for elderly women with low-risk breast cancer

Comparing 2 radiation treatments for elderly women with low-risk breast cancer

Posted by on May 15, 2021 in Breast cancer | 0 comments

In a nutshell This article compared the outcomes of older patients with low-risk breast cancer treated with accelerated partial breast irradiation (APBI) or ultra-APBI. The authors found that both treatment methods resulted in similar outcomes and side effects in these patients.  Some background Breast cancer is the most commonly diagnosed...

Read More

Evaluating the outcomes and safety of radiotherapy after immediate breast reconstruction following breast-conserving surgery

Evaluating the outcomes and safety of radiotherapy after immediate breast reconstruction following breast-conserving surgery

Posted by on Apr 30, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of radiotherapy (RT) after immediate autologous breast reconstruction (IABR) following breast-conserving surgery (BCS) in patients with breast cancer. The data showed that RT following IABR provided aesthetically satisfactory results with manageable side effects in these...

Read More

Chemotherapy versus endocrine therapy before surgery for invasive ductal carcinoma of the breast

Chemotherapy versus endocrine therapy before surgery for invasive ductal carcinoma of the breast

Posted by on Apr 18, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the effectiveness and safety of endocrine therapy (ET) or chemotherapy (CT) before surgery in patients with invasive ductal carcinoma (IDC) of the breast that is hormone receptor (HR) positive (+) and human epidermal growth factor receptor 2 (ERBB2) negative (-). The study concluded CT before...

Read More

Can intraoperative radiotherapy be used to treat early-stage breast cancer?

Can intraoperative radiotherapy be used to treat early-stage breast cancer?

Posted by on Mar 6, 2021 in Breast cancer | 0 comments

In a nutshell This article looked at 5-year outcomes of intraoperative radiation therapy (IORT) for breast cancer (BC). The authors found that IORT may have a higher rate of cancer return compared to whole-breast radiation therapy (WBRT). Some background BC is one of the most common forms of cancer found in women. Standard care for BC is usually a...

Read More

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor